Isofol Medical AB
5IU
Company Profile
Business description
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Contact
Arvid Wallgrens Backe 20
Biotech Center
GothenburgSE-413 46
SWET: +46 31137331
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
Despite recent AI jitters, strategists expect strong demand for Anthropic’s potentially historic IPO.
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
What inflation-resistant businesses have in common.
stocks
Our view after REA’s share price rally
A bullish market reaction but valuation concerns remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,175.20 | 30.50 | 0.33% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,820.36 | 504.65 | -1.92% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,529.67 | 47.81 | 0.20% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 59,374.86 | 1,940.09 | 3.38% |
| NZX 50 Index | 13,984.82 | 13.68 | -0.10% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,040.40 | 19.60 | 0.22% |
| SSE Composite Index | 3,665.94 | 16.77 | 0.46% |